Our data identify PPP3CB overexpression as a new mechanism of acquired resistance to EGFR TKI in EGFR-mutant NSCLC, and provide a promising therapeutic approach to overcome acquired resistance. Here, EGFR is linked to non-small cell lung carcinoma.